COMMUNIQUÉS West-GlobeNewswire

Longeveron Appoints Nirav Jhaveri as Chief Financial Officer
19/08/2026
Mr. Jhaveri has over 25 years of experience in capital markets, corporate finance, business development and investor relations, including more than 15 years in the biotech sector MIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE [...]
Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
19/08/2026
RESEARCH TRIANGLE PARK, N.C., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients [...]
Edesa Biotech Announces Proposed Public Offering
19/08/2026
TORONTO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA) (the “Company” or “Edesa”), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno- [...]
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
19/08/2026
WOBURN, Mass., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of [...]
FDA Authorizes First-of-Its-Kind Robotic Blood Draw Device
19/08/2026
Authorization supports innovative approach to blood collection; may help address growing phlebotomist shortage Silver Spring, Md., Aug. 19, 2026 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration today authorized [...]
Southern Sky Brands Announces Three New Vape Products in Collaboration with Martin’s in Jackson, Mississippi, Portions of Proceeds to Benefit Veterans Charity
19/08/2026
CANTON, Miss., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Southern Sky Brands is proud to announce the launch of three new vape products created in collaboration with Martin’s, the legendary Mississippi destination known for [...]
What Clinicians Evaluate Before Prescribing Low Dose Naltrexone Online
19/08/2026
Provn connects adults 18 and older with independent, U.S.-licensed clinicians who determine whether compounded low-dose naltrexone is medically appropriate. If prescribed, the strength, titration schedule, and [...]
Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial in Adults with Fibrodysplasia Ossificans Progressiva (FOP)
19/08/2026
FOP is an ultra-rare genetic disorder characterized by rogue bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability Approval based on results from [...]
Interim Report Q2 2026: Successful reception of Evolve3 headsets and gross margin improvement boding well for strong H2 2026
19/08/2026
Highlights The Enterprise division delivered organic revenue growth of -7%, while the organic revenue growth excl. FalCom ended at -3%. The development reflects continued strong growth in North America and APAC. The [...]
H1 2026: Novonesis delivered strong 8% organic sales growth and increases full-year outlook
19/08/2026
COPENHAGEN, Denmark – August 19, 2026. Novonesis delivered strong first half of 2026 at 8% organic sales growth. 2026 outlook: Organic sales growth increased to 7-8% (previously 5-7%), and the adjusted EBITDA margin [...]
Earth Science Tech, Inc. (ETST) Acquires Zoolzy LLC to Drive Margin Expansion and Strategic Entry into the Veterinary Market
19/08/2026
MIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) (“ETST” or the “Company”), a strategic holding company focused on a diversified portfolio, today announced the acquisition of Zoolzy LLC, a [...]
Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP
19/08/2026
August 19, 2026 Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP 87 subjects, over 50% of target, recruited Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “the Company”), a [...]
U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome
19/08/2026
Ecopipam (EBS-101) is a first-in-class selective D1 (dopamine) receptor antagonist with Orphan Drug designation NDA acceptance is supported by positive Phase 3 data, which were published in JAMA Neurology, and Phase 2b [...]
NOMAD Achieves UL 9540 Certification for 1 MW Transportable Battery Energy Storage System
19/08/2026
Certified Traveler system supports resilient power deployment for Missanabie Cree First Nation in Northern Ontario, Canada BOCA RATON, Fla., Aug. 19, 2026 (GLOBE NEWSWIRE) -- NOMAD Power Solutions Inc. ("NOMAD" or the " [...]
Intelligent Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth of 38% Year-over-Year, Driven by Reader Installed Base and High-Margin Cartridge Growth
19/08/2026
Reader installed base grew 22% year-over-year, driving a 35% increase in total consumable cartridges to over 100,000 units Full year gross profit margin expanded to 48.63%, up 778 basis points year-over-year 502 active [...]
Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update
19/08/2026
Proposed merger with Scipher Medicine to assess nebokitug in a Phase 2 precision medicine trial in rheumatoid arthritis (RA) continues to advance with closing expected by year-end RA is a $24 billion market with [...]
MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies
19/08/2026
ROCKVILLE, Md., Aug. 19, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and [...]
AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX®
19/08/2026
- Complementary peptide-mapping methods increased coverage of the active botulinum neurotoxin primary sequence from approximately 93% to 98%, with 100% amino acid identity across all regions analyzed - Preliminary [...]
Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD – The Liver Meeting® 2026
19/08/2026
WILMETTE, Ill., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with [...]

Pages